Humacyte

Humacyte Capital Intensity

The Capital Intensity Ratio of Humacyte (HUMA) as of Nov 21, 2026 is 5,709.81 %. In the previous year, Capital Intensity Ratio was 13,054.44 % — a change of -56.26% (lower).

Capital Intensity

5,709.81 %

YoY

-56.26%

Last updated:

Capital Intensity Ratio of Humacyte is 2025 5,709.81 % . Capital Intensity Ratio of Humacyte was 2024 13,054.44 % . It decreases by -56.26% lower compared to the previous year.

The Humacyte Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2019
2,726.54 USD
Jan 1, 2020
7,155.47 USD
Jan 1, 2021
22,686.70 USD
Jan 1, 2022
13,054.44 USD
Jan 1, 2025
5,709.81 USD
The Humacyte Capital Intensity history
YEARCapital IntensityYoY
5,709.81 %-56.26%
13,054.44 %-42.46%
22,686.70 %+217.05%
7,155.47 %+162.44%
2,726.54 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humacyte Stock analysis

What does Humacyte do? Humacyte, Inc. develops and manufactures off-the-shelf, universally implantable bioengineered human tissues and advanced tissue constructs. The company focuses on human acellular vessels (HAVs) targeting vascular repair, reconstruction, and replacement markets, including vascular trauma, AV access for hemodialysis, peripheral arterial disease, and coronary artery bypass grafting. HAVs are also being developed for pediatric heart surgery and cellular therapies like pancreatic islet cell transplantation for Type 1 diabetes. The company's technology platform uses primary human aortic vascular cells to mimic human physiology. Humacyte's products are sold to healthcare providers and medical institutions for surgical procedures requiring tissue replacement. The vascular repair and hemodialysis markets represent key segments where HAVs address unmet clinical needs. Pediatric heart surgery applications target specialized medical centers, while cellular therapy delivery focuses on diabetes treatment centers. The company's novel manufacturing paradigm enables universal implantability without immune rejection. The firm's revenue streams derive from the sale of HAVs for vascular procedures and their expansion into pediatric and cellular therapy applications. Market segments include vascular surgery, nephrology for hemodialysis access, and endocrinology for diabetes treatment. HAVs are positioned as a solution for patients requiring tissue grafts with reduced risk of rejection compared to traditional methods. Humacyte is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humacyte stock

Capital Intensity Ratio of Humacyte is 5,709.81 % in 2025.

Capital Intensity Ratio of Humacyte changed from 13,054.44 % to 5,709.81 %, representing a -56.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Humacyte since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Humacyte with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Humacyte

All Key Metrics — Humacyte